Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity

• Published in: Translational research : the journal of laboratory and clinical medicine Vol. 153; no. 4; pp. 190 - 198
• Main Authors: Harangi, Mariann, Mirdamadi, Hossein Z, Seres, Ildikó, Sztanek, Ferenc, Molnár, Miklós, Kassai, Andrea, Derdák, Zoltán, Illyés, László, Paragh, György
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.04.2009; Elsevier
• Subjects: Adult; Aged; Aryldialkylphosphatase - blood; Atorvastatin Calcium; Biological and medical sciences; Cholesterol Ester Transfer Proteins - blood; General aspects; Heptanoic Acids - pharmacology; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Internal Medicine; Investigative techniques, diagnostic techniques (general aspects); Lipoproteins, HDL - blood; Medical sciences; Middle Aged; Phosphatidylcholine-Sterol O-Acyltransferase - blood; Pyrroles - pharmacology; CETP; cholesteryl ester transfer protein; high-density lipoprotein; low-density lipoprotein cholesterol; PON1; LCAT; apolipoprotein A1; lecithin-cholesterol acyltransferase; HDL; LDL; VLDL; high-density lipoprotein cholesterol; ApoA1; oxLDL; hydroxy-3-methylglutaryl coenzyme A; small dense low-density lipoprotein; sdLDL; LDL-c; HMG-CoA; human serum paraoxonase-1; low-density lipoprotein; HDL-c; very low-density lipoprotein; coronary heart disease; oxidized low-density lipoprotein; CHD; Human; Enzyme; Enzyme inhibitor; Statin derivative; Esterases; Hypocholesterolemic agent; Biological activity; Medicine; Phosphoric triester hydrolases; HMG-CoA reductase inhibitor; Clinical biology; Distribution; Atorvastatin; Hydrolases; Hydroxymethylglutaryl-CoA reductase; Oxidoreductases; Aryldialkylphosphatase; Pharmacokinetics; Lipoprotein HDL; Antilipemic agent
• ISSN: 1931-5244; 1878-1810
• DOI: 10.1016/j.trsl.2009.01.007

Human serum paraoxonase-1 (PON1) protects lipoproteins against oxidation by hydrolyzing lipid peroxides in oxidized low-density lipoprotein (LDL); therefore, it may protect against atherosclerosis. Changes in the ratio of high-density lipoprotein (HDL) subfractions may alter the stability and the antioxidant capacity of PON1. The aim of the study was to examine the effect of atorvastatin treatment on the distribution of HDL subfractions, LDL size, cholesteryl ester transfer protein (CETP), lecithin-cholesterol acyltransferase (LCAT), and PON1 activity. In all, 33 patients with type IIa and IIb hypercholesterolemia were involved in the study. LDL sizes and HDL subfractions were determined by gradient gel electrophoresis. CETP, LCAT, and PON1 activities were measured spectrophotometrically. Three months of treatment with atorvastatin 20 mg daily significantly increased the HDL3 (+8.13%) and decreased the HDL2a and HDL2b subfractions (–1.57% and –6.55%, respectively). The mean LDL size was significantly increased (+3.29%). The level of oxidized LDL was significantly decreased (–46.0%). The PON1 activity was augmented by the atorvastatin treatment (+5.0%). The CETP activity positively correlated with the HDL2b level and negatively correlated with the HDL3 and HDL2a levels. Atorvastatin alters the HDL subfractions, which may improve its antiatherogenic effect via enhancement of the PON1 activity.